

## Publication List: Laura Suter-Dick (4/10/2019)

### Peer reviewed journals

1. Three parameter flow cytometric analysis of rat spermatogenesis. **Suter L**, Koch E, Bechter R and Bobadilla M. *Cytometry* 27: 161-168 (1997).
2. Flow cytometric evaluation of the effects of doxorubicin on rat spermatogenesis. **Suter L**, Bobadilla M, Koch E and Bechter R. *Reproductive Toxicology* 11 (4): 521-431 (1997).
3. New and traditional approaches for the assessment of testicular toxicity. **Suter L**, Clemann N, Bobadilla M and Bechter R. *Reproductive Toxicology* 12 (1): 39-47 (1998).
4. Characterization of mouse epididymal acrosin: comparative studies with acrosin from boar and human ejaculated spermatozoa. **Suter L**, Habenicht U-F; *Int. J. Androl.*, 21: 95-104 (1998).
5. Flow cytometry as a sensitive tool to assess testicular damage in the rat. **Suter L**, Meier G, Bechter R and Bobadilla M; *Arch. Toxicol.*, 72: 791-797 (1998).
6. Two-dimensional database of mouse liver proteins. Changes in hepatic protein levels following treatment with acetaminophen or its non-toxic regioisomer 3-acetamidophenol. Fountoulakis M, Berndt P, Boelsterli UA, Cramer F, Winter M, Albertini S and **Suter L**. *Electrophoresis*: 21(11): 2148-61 (2000).
7. Proteome analysis of the rat liver. Fountoulakis M, **Suter L**. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002 Dec 25;782(1-2):197-218
8. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Fountoulakis M, de Vera M-C, Cramer F, Boess F, Gasser R, Albertini S, **Suter L**. *Toxicol. Appl. Pharmacol.*, 183, 71-80 (2002).
9. The rat liver mitochondrial proteins. Fountoulakis M, Berndt P, Langen H, **Suter L**. *Electrophoresis* 2002 Jan; 23(2):311-28
10. Gene expression in two hepatic cell lines, cultured primary hepatocytes and liver slices compared to in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Boess F., M. Kamber, S. Romer, R. Gasser, D. Müller, S. Albertini and **L. Suter**. *Tox Sci*, 73: 386-402 (2003)
11. Effect of two 5-HT6 receptor antagonists on the rat liver, a molecular approach. **Suter L.**, Haiker M, de Vera M.C., Albertini S. *The Pharmacogenomics Journal*, 3: 320-334 (2003).
12. Fractionation of liver proteins by preparative electrophoresis. Fountoulakis, M., Juranville, J. F., Tsangaris, G., **Suter, L**. *Amino Acids*, 26/1: 27-36 (2004).
13. Toxicogenomics in predictive toxicology in drug development. **Suter L**, Babiss LE, Wheeldon EB, *Chemistry & Biology*, 11/2: 161-171 (2004).

14. Interlaboratory Evaluation of Rat Hepatic Gene Expression Changes Induced by Methapyrilene. Waring JF, Ulrich RG, Flint N, Morfitt D, Kalkuhl A, Staedtler F, Lawton M, Beekman JM, **Suter L**. *Environ Health Perspect. Toxicogenomics*, 112 (4): 439-448 (2004).
15. Discriminating different classes of toxicants by transcript profiling. Steiner G, **Suter L**, Boess, F., Gasser, R., de Vera, M. C., Albertini, S., Ruepp, S. *Environ Health Perspect. Toxicogenomics* 112, 1236-48 (2004).
16. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Luhe, A., **Suter, L.**, Ruepp, S., Singer, T., Weiser, T., and Albertini, S. *Mutat Res*, 575, 102-15 (2005).
17. Assessment of hepatotoxic liabilities by transcript profiling. Ruepp S., Boess F., **Suter L.**, de Vera M. C., Steiner G., Steele T., Weiser T., Albertini S. *Toxicol Appl Pharmacol*, Sep 1; 207 (2 Suppl):161-70 (2005).
18. Beekman J.B., Boess F., Hildebrand H., Kalkuhl A., and **Suter L**: Gene expression analysis of the hepatotoxicant methapyrilene in primary rat hepatocytes: an interlaboratory study. *Environ Health Perspect. Toxicogenomics*, 114 (1): 92-9 (2006).
19. Meistermann H., Norris J.L., Aerni H.-R., Augustin A., Friedlein A., Berndt P., De Vera Mudry M.-C., Ruepp S., **Suter L.**, Langen H., Caprioli R.M., Ducret A. Transthyretin is a Biomarker for Gentamicin-Induced Nephrotoxicity in Rat: Investigation of a case study by imaging mass spectrometry. *Molecular and Cellular Proteomics*. Oct; 5 (10):1876-1886 (2006).
20. Boess F., Durr E., Schaub N., Haiker M., Albertini S., **Suter L**. An in vitro study on 5-HT6 receptor antagonist induced hepatotoxicity based on biochemical assays and toxicogenomics. *Toxicology in vitro*, 21(7): 1276-86. (2007).
21. Dieterle F, Schlotterbeck G, Binder M, Ross A, **Suter L** and Senn H. Application of metabolomics in a competitive profiling study in early drug development reveals N-acetyl-felinine excretion as biomarker for inhibition of the farnesyl pathway by bisphosphonates. *Chem Res Tox.* 20(9): 1291-9. (2007).
22. Lühe A, Künkele K-P, Haiker M, Schad K, Zihlmann C, Bauss F, **Suter L**, Pfister T. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. *Toxicology in vitro* 22(4):899-909 (2008).
23. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, **Suter L**, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring

- J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W. The PSTC Renal Biomarker Qualification Submission and FDA/EMA Decisions: Conclusions and Implications of First Formal Qualification Submission. *Nature Biotechnology* 28(5):455-62 (2010).
24. M. Adler, D. Hoffmann, H. Ellinger-Ziegelbauer, P. Hewitt, K. Matheis, L. Mulrane, W.M. Gallagher, J.J. Callanan, **L. Suter-Dick**, M. M. Fountoulakis, W. Dekant, A. Mally. Assessment of candidate biomarkers of drug induced liver injury in preclinical toxicity studies, *Toxicol. Letters*, 196(1):1-11. (2010).
  25. Mikaelian I, Buness A, Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, Char HW, Carvajal V, Hilton H, Funk J, Hoflack JC, Fielden M, Herting F, Dunn M, **Suter-Dick L**. Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs. *Tox Sci* 117(1): 144–151 (2010).
  26. Roth A, Boess F, Landes C, Steiner G, Freichel C, Plancher J-M, Raab S, de Vera Mudry C, Weiser T, **Suter L**. Gene expression-based in vivo and in vitro prediction of liver liability allow compound-selection at an early stage of drug development. *Journal of Biochemical and Molecular Toxicology*, 25:183-194 (2011).
  27. H. Ellinger-Ziegelbauer, M. Adler, A. Amberg, A. Brandenburg, J.J. Callanan, S. Connor, M. Fountoulakis, H. Gmuender, A. Gruhler, P. Hewitt, M. Hodson, K.A. Matheis, D. McCarthy, M. Raschke, B. Riefke, C.S. Schmitt, M. Sieber, A. Sposny, **L. Suter**, B. Sweatman, A. Mally. The enhanced value of combining conventional and “omics” analyses in early assessment of drug-induced hepatobiliary injury. *Toxicology and Applied Pharmacology*, 252: 97-111 (2011).
  28. **L. Suter**, S. Schroeder, K. Meyer, J-C Gautier, A. Amberg, M. Wendt, H. Gmuender, A. Mally, E. Boitier, H. Ellinger, K. Mattheis, F. Pfannkuch. EU Framework 6 Project: Predictive Toxicology (PredTox) – Overview and Outcome. *Toxicology and Applied Pharmacology*, 252: 73-84 (2011).
  29. K. A. Matheis, E. Com, J-C. Gautier, N. Guerreiro, A. Brandenburg, H. Gmuender, A. Sposny, P. Hewitt, A. Amberg, O. Boernsen, B. Riefke, D. Hoffmann, A. Mally, A. Kalkuhl, **L. Suter**, F. Dieterle, F. Staedtler. Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. *Toxicology and Applied Pharmacology*, 252: 112-122 (2011).
  30. I. Mikaelian, A. Buness, G. Hirkaler, R. Fernandes, D. Coluccio, W. Geng, T. Visalli, M. O. Bachynsky, H. Hilton, R. Nicklaus, J.-C. Hoflack, M. Dunn, M. Sanders, **L. Suter Dick**. Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone *Toxicology Letters*; 201(2):110-115 (2011).
  31. E. Boitier, A. Amberg, V. Barbié, A. Blichenberg, A. Brandenburg, H. Gmuender, A. Gruhler, D. McCarthy, K. Meyer, B. Riefke, M. Raschke, W. Schoonen, M. Sieber, **L. Suter**, C. E. Thomas, N. Sajot. An integrated transcriptomics and proteomics functional characterization of liver hypertrophy in the rat. *Toxicology and Applied Pharmacology*, 252: 85-96 (2011).

32. A. Corsini, P. Ganey, C. Ju, N. Kaplowitz, D. Pessayre, R. Roth, P. Watkins, M. Albassam, B. Liu, S. Stancic, **L. Suter**, M. Bortolini. Current Challenges and Controversies in Drug-Induced Liver Injury. *Drug Safety*, 35 (12): 1099-1117 (2012).
33. L. Doessegger, G. Schmitt, B. Lenz, H. Fischer, G. Schlotterbeck, E--A. Atzpodien, H. Senn, **L. Suter**, M. Csato, S. Evers, T. Singer. Increased levels of urinary phenylacetyl-glycine associated with mitochondrial toxicity in a model of drug- induced phospholipidosis. *Therapeutic Advances in Drug Safety*, 4: 101-114 (2013).
34. R. M. Kostadinova, F. Boess, D. R. Applegate, **L. Suter**, T. Weiser, T. Singer, B. A. Naughton, A. Roth. A Long-Term Three Dimensional Liver Co-Culture System for Improved Prediction of Clinically Relevant Drug-Induced Hepatotoxicity. *Tox. Appl. Pharmacol.*, 268: 1-16 (2013).
35. L. Bailey, L. Moreno, T. Manigold, H. Kropshofer, H. Hinton, T. Singer, **L. Suter**, T. T. Hansel and J. A. Mitchell. A simple whole blood bioassay to detect the propensity of biotherapeutic antibodies such as anti-CD28SA to cause a cytokine storm. *Journal of Pharmacological and Toxicological Methods*, 68: 231-239 (2013).
36. F. Boess, C. Bertinetti-Lapatki, S. Jensen-Zoffmann, C. George, T. Pfister, A. Roth, S.M.L. Lee, W. Thasler, T. Singer, **L. Suter**. Effects of GLP-1 R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. *J. Mol Endocrinol*, 50: 325-336 (2013).
37. T. M. DesRochers, **L. Suter**, A. Roth, D. L. Kaplan. Bioengineered 3D Human Kidney Tissue, a Platform for the Determination of Nephrotoxicity. *PLOS One. ePub* (2013).
38. K. M. Dudek, **L. Suter**, V. M. Darras, E. L. Marczylo, and T. W. Gant. Decreased translation of Dio3 mRNA is associated with drug-induced hepatotoxicity. *Biochem J.* 453(1):71-82. (2013).
39. Kustermann S, Boess F, Buness A, Schmitz M, Watzele M, Weiser T, Singer T, **Suter L**, Roth A. A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects. *Toxicol In Vitro* 27(5):1589-95 (2013).
40. Kustermann S, Manigold T, Ploix C, Skubatz M, Heckel T, Hinton H, Weiser T, Singer T, **Suter L**, Roth A. A Real-time Impedance-Based Screening Assay for Drug-Induced Vascular Leakage. *Toxicol Sci.* 138(2):333-43 (2014).
41. Buness A, Roth A, Herrmann A, Schmitz O, Kamp H, Busch K, **Suter L**. Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity. *PLOS One* 9 (5): e97249 (2014).
42. **L. Suter-Dick**, R.F. Prétôt, G.J. Chen. Molecular and in vitro Toxicology at the FHNW. *Chimia (Aarau)*. 2014;68(5):329-30.
43. **L. Suter-Dick**, PM Alves, BJ Blaauboer, KD Bremm, C Brito, S. Coecke, B. Flick, P. Fowler, J. Hescheler, M. Ingelman-Sundberg, P. Jennings, J.M. Kelm, I. Manou, P. Mistry, A. Moretto, A. Roth, D. Stedman, B. van

de Water, M. Beilmann. Stem cell derived (SCD) systems in toxicology assessment. *Stem Cells and Development*, 2015. *e-print*..

44. MJ Wilmer, C. PingNg, HL Lanz, P Vulto, **L Suter-Dick** and R Masereeuw: Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. *Trends in Biotechnology*, Vol. 34, No. 2 (2016)
45. F.A. Atienzar, E.A. Blomme, M Chen, P. Hewit, J. G., G. Labbe, F. Moulin, F. Pognan, A.B. Roth, L. Suter-Dick, O. Ukairo, R. Weaver, Y. Will, D. Dambach. Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans. *BMRI 2016:9737920* (2016).
46. V. Prestigiacomo, A. Weston, S. Messner, F. Lampart, **L. Suter-Dick**. Pro-Fibrotic Compounds Induce Stellate Cell Activation, ECM-Remodelling and Nrf2 Activation in a Human 3D-Multicellular Model of Liver Fibrosis. *PLOS One*, 12 (6) (2017).
47. **Suter-Dick L**, Mauch L, Ramp D, Caj M, Vormann MK, Hutter S, Lanz HL, Vriend J, Masereeuw R, Wilmer MJ.: Combining extracellular miRNA determination with microfluidic 3D-cell cultures for the assessment of nephrotoxicity. *AAPS J.* 2018 Jul 23;20(5):86. doi: 10.1208/s12248-018-0245-2. (2018).
48. V. Prestigiacomo, **L. Suter-Dick**: Nrf2 protects stellate cells from Smad-dependent cell activation. *PLOS One*, 13 (7) (2018.).
49. Vormann MK, Gijzen L, Hutter S, Boot L, Nicolas A, van den Heuvel A, Vriend J, Ng CP, Nieskens TTG, van Duinen V, de Wagenaar B, Masereeuw R, **Suter-Dick L**, Trietsch SJ, Wilmer M, Joore J, Vulto P, Lanz HL. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules. *AAPS J.* Aug 14;20(5):90. doi: 10.1208/s12248-018-0248-z (2018).
50. Vriend J, Nieskens TTG, Vormann MK, van den Berge BT, van den Heuvel A, Russel FGM, **Suter-Dick L**, Lanz HL, Vulto P, Masereeuw R, Wilmer MJ. Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip. *AAPS J.* 2018 Jul 26;20(5):87. doi: 10.1208/s12248-018-0247-0.

## Books and Book Chapters:

1. How could things be done better using Toxicogenomics? A retrospective analysis. **L Suter**, R Gasser for Handbook of Toxicogenomics (Textbook) published by Wiley-VCH (ed. J. Borlak), pp. 561-582, 2005.
2. Omics in Toxicology. **Suter-Dick L**, Singer T for Toxicology and Risk Assessment: A Comprehensive Introduction (Textbook), published by Wiley-VCH (eds. H. Greim & R. Snyder), pp. 437-448, 2008.
3. Use of Toxicogenomics as an early predictive tool for hepatotoxicity **Suter L**, In "Toxicogenomics, a powerful tool for toxicity assessment" published by Wiley-VCH (eds. Saura C Sahu), pp. 235-251, 2008.
4. High-throughput flow cytometry for predicting drug-induced hepatotoxicity. Zanese M, **Suter L**, Roth A, DeGiorgi F, Ichas F for Clinical Flow Cytometry-Emerging Applications, published by InTech (ed. I. Schmid), pp. 43-60, 2012.
5. 'Omics in organ toxicity, integrative analysis approaches, and knowledge generation. L. Suter-Dick. In "Toxicogenomics-based cellular models", published by Elsevier (ed. J. Kleinjans), pp 235-248, 2014.
6. Co-Editor and co-author of the Book on "Predictive Toxicology - From Vision to Reality", published by Wiley (eds. F. Pfannkuch and **L. Suter-Dick**), 2015
7. Omics in der Toxikologie. **L. Suter-Dick** for Das Toxikologiebuch: Grundlagen, Verfahren, Bewertung (Textbook), published by Wiley-VCH (ed. H. Greim), pp. 591-607, 2017.
8. Omics in Toxicology. L. Suter-Dick for Toxicology and Risk Assessment: A Comprehensive Introduction (Textbook), published by Wiley-VCH (ed. H. Greim), second edition, 2018.

## Selected Oral Communications

Free communication at the founding meeting of the Swiss Cytometry Society in Lausanne, Switzerland (11 March 1995). Title of the presentation: "Flow cytometric detection of DNB toxicity on rat spermatogenesis." (**Suter L.**, Koch E., Bechter R. and Bobadilla M.)

"Potential Application of DNA-Chip Technology (Microarray) in Toxicology". Silvio Albertini and **Laura Suter-Dick**. Oral presentation at the 31<sup>st</sup>. Annual Meeting of the European Environmental Mutagen Society (EEMS), September 1-5, 2001 Ghent, Belgium.

Lecture (Vorlesung 4526: Genetic approaches in molecular, biomedical and pharmacological research; invited by Dr. Raija Lindberg, P.D) at the University of Basel, "Using microarrays to characterize toxicity", 21. November 2001.

Invited speaker: Training Course on High-throughput (HT) Drug Metabolism/Disposition, Organised by the European Federation for Pharmaceutical Sciences (EUFEPS). April 29, 2004, Amsterdam, The Netherlands.

Invited Speaker "Application of "Omics" Technologies in Integrated Safety Assessment". **Laura Suter-Dick**. Presented at the EFPIA/CHMP first joint meeting on The Emerging Use of 'Omic Technologies in Regulatory Non-clinical Safety Testing. October 26-27, 2004, Bonn, Germany.

Invited Speaker "Application of "omics" technologies for the prediction of hepatotoxicity and for the identification of safety biomarkers". **L. Suter-Dick**, S. Ruepp, S. Evers, G. Steiner, E. Laczko, T. Weiser. Presented at "Exploring the functional genomics and proteomics of liver in health and disease" from the AASLD .June 3-5, 2005, Warrenton, VA, USA.

Invited Speaker "Applications of 'omic technologies in integrated safety assessment". **L. Suter-Dick**, E. Laczko, F. Dieterle, S. Evers, S. Ruepp, S. Albertini, T. Weiser. Presented at the Pharmaceutical Sciences Fair & Exhibition, June 12-17 2005, Nice, France.

Lecture (Vorlesung invited by Prof. Daniel Dietrich) at the University of Konstanz, "Toxicogenomics in the Pharma Industry: Technologies and Applications in vivo and in vitro." 16. December 2005, Konstanz, Germany.

Lecture (Vorlesung invited by Prof. Raija Lindberg) at the University of Basel, "Application of "omics" technologies in integrated safety assessment". 09 May 2006, Biozentrum Basel, Switzerland.

Invited speaker: Training Course on High-throughput (HT) Drug Metabolism/Disposition, Organised by the European Federation for Pharmaceutical Sciences (EUFEPS). May 28 – June 02, 2006, Amsterdam, The Netherlands.

Co-organizer of the Post-graduate course on "Applications of Toxicogenomics in Biotechnology Workshop": Peter Lord, **Laura Suter-Dick** and Yus

Sharifuddin sponsored by the Malaysian Genomics Institute (25-29 October 2010).

Speaker at the IMI (Innovative Medicine Initiative) open information day, June 17, 2011 in Brussels, Belgium. Title: hiPS cells for Drug Discovery and Safety Assessment.

Speaker at the joint EPAA/DG JRC expert meeting on the use of stem cells in toxicological research programmes on the October 4-5, 2011 in Ispra, Italy.

Invited lecturer at the III Scientific Congress from AEFUL on Advanced Therapies: A Pharmaceutical Reality? Stem cells for discovery and safety research. Hosted by the University of Lisbon on November 25, 2011 in Lisbon, Portugal.

Invited chair and speaker of the parallel session on Omics and bioinformatics in drug efficacy and safety at the 12th European ISSX meeting to be held on June 17-21, 2012 in Noordwijk aan Zee, The Netherlands.

Invited speaker at the MipTec, session on Early Toxicology Evaluation: "European IMI StemBancc Initiative: iPSC-derived cell models", September 24-27 2012, Basel, Switzerland.

Invited Speaker and Co-Chair of the Workshop on "Cellular models for drug metabolism, transport and toxicity" at the 20<sup>th</sup> International Symposium on Microsomes and Drug Oxidations, May 18 2014, Stuttgart, Germany.

Invited Speaker and Chair of the Session on "Stem cell technology for research and drug development" at the 20<sup>th</sup> International Symposium on Microsomes and Drug Oxidations, May 18-22 2014, Stuttgart, Germany

Invited Speaker and Co-Chair of the Session on "Advanced in vitro models" at The 18th International Congress on In Vitro Toxicology (ESTIV) 2014 June 10-14 2014, Egmond aan Zee, The Netherlands.

Invited speaker at the American Association Pharmaceutical Scientist annual meeting "Applications of cell models in drug safety and drug development", 19-22 April 2015, Baltimore, USA.

Invited speaker at the Tissue Engineering for Drug Discovery (TEDD) annual meeting "Human 3D-cocultures for the study of liver fibrosis", October 2016, Wädenswil, Switzerland.

Invited Speaker at the 3D Printing for Life Sciences, organized by Basel area Swiss "Bioprinting for drug discovery and toxicology", July 2017, Muttenz, Switzerland.

Invited Speaker and Co-Chair of the Workshop on "Stem cell systems and 3D technologies: Implementation for in vitro liver toxicology assessment" at The Eurotox 2017, September 2017, Bratislava, Slovakia.



Invited Speaker at the Open Tox Basel 2017: “Liver fibrosis: Corroboration and improvement of the existing AOP using in vitro data”, November 2017, Basel, Switzerland.

Invited Speaker at the Annual Meeting 2017 of the Swiss Society of Toxicology: “Testing the influence of neuroinflammation on neurotoxicity in vitro”, November 2017, Basel, Switzerland.

## **Selected poster Presentations**

Poster presentation at the First European Congress of Pharmacology at the University of Milan, Italy (June 1995). Published in the abstract book: "Effect of DNB on rat spermatogenesis." (**Suter L**, Bobadilla M, Koch E and Bechter R).

Poster and oral presentation at the Workshop on Reproductive Toxicology in Granada, Spain (October 1997): "Flow cytometry as a tool for the evaluation of testicular toxicity." (Bobadilla M, **Suter L** and Bechter R). In: *Reproductive Toxicology* Ed. by del Mazo, Plenum Press, New York: 73-78 (1998).

Poster presentation: "Toxicogenomics: correlation of acetaminophen-induced hepatotoxicity with gene expression using DNA microarrays. " **Suter L**, Boelsterli UA, Winter M, Cramer F, Gasser R, Bedoucha M, de Vera C and Albertini S. *Toxicological Sciences*, Vol 54 (1): 383 (2000). SOT, March 2000, Pennsylvania.

Poster Presentation: The rat liver mitochondrial proteins. Fountoulakis, M., Juranville, J.-F., and **Suter, L**. Presented at the International Electrophoresis '01 Meeting, June, 10-14, 2001, Verona, Italy.

Poster Presentation: Modulation of protein and gene expression by the hepatotoxin carbon tetrachloride. Fountoulakis, M., Juranville, J.-F., and **Suter, L**. Presented at the International Electrophoresis '01 Meeting, June, 10-14, 2001, Verona, Italy.

Poster Presentation: "Toxicogenomics: Fingerprinting toxic compounds using gene expression profiles". **Suter-Dick L**, Boess F, Gasser R, de Vera C, Cramer F, Bedoucha M, Evers S, Albertini S. Selected for a poster discussion session at the SOT, March 2002, Nashville.

Poster Presentation: "Hepatic gene expression in a Concanavalin A induced model of liver injury in the rat." M. Winter, M. Bedoucha, F. Cramer, **L. Suter**, N. Flint, R. Gasser, S. Albertini, U. Boelsterli. Presented at the 3<sup>rd</sup>. International Congress of Autoimmunity, February 20-24, 2002, Geneva, Switzerland.

Poster Presentation: "Compound classification using transcript profiling". Ruepp S, Steiner G, Boess F, Gasser R, Evers S, de Vera MC, Albertini S, **Suter L**. Presented at the SOT, March 2004, Baltimore, USA.

Poster Presentation "Gene Expression Profile of the Myocardium and Peripheral Blood Leukocytes in Isoproterenol-Induced Cardiomyopathy in Rats." Coluccio D, Mikaelian I, Nicklaus R, Lamb M, Rasmussen E, **Suter L**, Barrett P, Wheeldon EB. Presented at the AACCC, 2005, USA.

Poster Presentation "Mechanistic investigations on mouse specific toxicity with a PPAR $\alpha,\gamma$  co-agonist". Boess F, **Suter L**, Atzpodien E, Hoffmann G,

Bopst M. Presented at the SOT 45<sup>th</sup>. Annual Meeting, March 2006, San Diego, USA.

Poster Presentation **L. Suter**, S. Schroeder, K. Meyer, H. Gmuender, J.-C. Gautier, E.-R. Troesken, A. Amberg, M. Wendt Poster Presentation at the Conference: Gordon Research Conferences, TOXICOGENOMICS; June 24-29, 2007; Colby-Sawyer College; New London, NH: Integration of 'omics data in toxicology: The PredTox collaborative project as part of the EU Framework 6 program.

Poster Presentation Transcriptomic analysis reveals mechanism underlying the off-target effect of the cholesteryl-ester transfer protein inhibitor Torcetrapib. Hoflack JC, Flint N, Haiker M, Stauffer A, **Suter-Dick L**, Roth A, Weiser T, Singer T, Müller L, Niesor EJ and Clerc RG. SOT 2011, Washington DC.

Poster Presentation Importance of IL-6 signaling for mitochondrial STAT3 expression and mitochondrial function in mouse liver. F Boess, A Roth, K Schad, Ch Zihlmann, M Bellot, A Olaharski, **L Suter**, S Platz, T Weiser, T Singer, L Mueller SOT 2011, Washington DC.

Poster Presentation Gene expression and morphological analysis of heart and liver from IL-6 KO mice. A Roth, F Boess, J-C Hoflack, Ch Landes, M Bellot, A Olaharski, **L Suter**, S Platz, T Weiser, T Singer, L Mueller SOT 2011, Washington DC.

Poster Presentation A 3-dimensional liver model for the safety-evaluation of drug candidates Kostadinova R M, Boess F, **Suter L**, Weiser T, Singer T, Roth A SOT 2011, Washington DC.

Platform Presentation Plasma miRNAs are early markers of drug-induced liver injury in the rat. Cristina Bertinetti-Lapatki, Igor Mikaelian, Susanne Fischer, Anne Eichinger-Chapelon, Tanja S. Zabka, Thomas Weiser, Mudher Albassam, Thomas Singer, **Laura Suter** SOT 2012, San Francisco.

Poster Presentation Establishment of in vitro models for the pre-clinical safety evaluation of therapeutic siRNA. C. Bertinetti-Lapatki, C. Ploix, M. Ravon, **L. Suter**, T. Weiser, U. Certa, T. Singer, H. Hinton SOT 2012, San Francisco.

Poster Presentation Establishment of rodent cell culture in vitro systems for the investigation of testicular toxicity. Y. Brunner, P. Giron, C.M. Pastore, P. Antinori; A. Scherl, **L. Suter**, S. Kustermann, T. Weiser, T. Singer, D. Hochstrasser; L. Stoppini. ESTIV, 2012; Lisbon, Portugal.

Poster (selected for oral presentation): Cytotoxicity, beyond cell death. R. Pretot, V. Prestigiaco, T. Horat, V. Butterweck, **L. Suter**. ESTIV 2014; Egmond aan Zee, The Netherlands.

Poster (selected for oral presentation): Secreted and intracellular miRNAs as biomarkers for hepatic toxicity in vitro. S.Fischer, R. Pretot, F. Boess, A. Roth,

**L. Suter**, C. Bertinetti-Lapatki. ESTIV 2014; Egmond aan Zee, The Netherlands.

Poster presentation Human, 3D-model for the investigation of hepatic fibrosis V. Prestigiacomo, **L. Suter-Dick**. Eurotox 2015, Porto, Portugal

Poster presentation High throughput in vitro system for nephrotoxicity testing. R. Prétôt, A. Weston, I. Wegner, M.J. Wilmer, T.T.G. Nieskens, P. Vulto, J. Joore, H. Lanz, R. Masereeuw, **L. Suter-Dick**. Eurotox 2015, Porto, Portugal

Poster (selected for oral presentation): Human, 3D-cocultures for the study of toxicant induced liver fibrosis. Vincenzo Prestigiacomo, Franziska Lampart, **Laura Suter-Dick**. ESTIV 2016; Juan les Pins, France.

Poster: Design of kidney structures to be cultured under flow. Philip Chavanne, Marina Beauflis, David Hradezky, **Laura Suter-Dick**. ESTIV 2016; Juan les Pins, France.

Poster: Standardized 3D-cell culture systems for the evaluation of cytostatica. Roberta Vazzana, **Laura Suter-Dick**. Dechema 2016, Freiburg, Germany

Poster: 3D-cultures of MCF-7 cells resemble tumor phenotype. Salvatore Mannino, **Laura Suter-Dick**. TEDD Annual meeting 2016, Wädenswil, Switzerland.

Poster (selected for oral presentation): A three dimensional, human co-culture model for the study of mechanisms in Alzheimer's disease. **L. Suter-Dick**, Carine Gaiser. AD/PD 2017, Vienna, Austria.

Poster (winner Astra Zeneca Award): Human, 3D-cocultures for the study of toxicant induced liver fibrosis. V. Prestigiacomo, **L. Suter-Dick**. Eurotox 2017, Bratislava, Slovakia.

Poster: 3D human liver microtissues as an in vitro tool for testing fibrogenic compounds. C. Pilling, V. Prestigiacomo, S. Mannino, **L. Suter-Dick**. Swisstox, 2017, Basel, Switzerland.

Poster: Mechanisms of liver fibrosis: TGF- $\beta$ 1 and PDGF trigger different aspects of stellate cell activation. V. Prestigiacomo, C. Bongiovanni, **L. Suter-Dick**. Swisstox 2017, Basel, Switzerland.